CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of renal cell carcinoma (RCC).
  
  OVERVIEW OF ACTIVITY
  An estimated 73,820 cases of cancers of the kidney and renal pelvis will be identified in the United States in the year 2019, and 14,770 individuals will die from these diseases. Approximately 85% of kidney tumors are RCC, and approximately 70% of patients with this disease type have clear cell histology. The past several years have seen an explosion in the emergence of new potential immune-mediated therapies, the most recent of which are known as immune-modulating antibodies or checkpoint immune modulators that leverage the natural ability of the human body to attack and treat cancer, and a small subset of patients with metastatic RCC (mRCC) have exhibited impressive and often durable responses with these approaches. Equally relevant, these approaches have also been shown to induce durable survival benefits while often introducing limited toxicity. Since the FDA granted regulatory approval in 2015 for the use of an anti-PD-1 antibody monotherapy as treatment for patients with advanced RCC who have received prior anti-angiogenic therapy, targeting multiple immune checkpoints in patients with advanced disease has also yielded impressive outcomes. Another research strategy that has been broadly pursued more recently for RCC has been the use of anti-PD-1/PD-L1 antibodies in combination with other targeted agents, with the FDA approving a number of these combinations in both the previously treated and first-line settings for advanced disease.
  
  Not surprisingly, with the many exciting advances rapidly occurring, a number of vexing clinical challenges are emerging simultaneously related to the role of immunotherapeutic combinations. To bridge the gap between research and patient care, this program features a joint discussion with 2 leading genitourinary cancer clinical investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity will assist medical oncologists with the formulation of up-to-date clinical management strategies for patients with RCC.
  
  LEARNING OBJECTIVES

  • Evaluate published research findings documenting the efficacy and safety of immune checkpoint inhibition for patients with mRCC, and appreciate the role of these agents in current treatment algorithms.
  • Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for patients with mRCC, and develop strategies to appropriately integrate this strategy into the care of these individuals.
  • Appraise available clinical trial data evaluating the use of recently FDA-approved anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for patients with previously untreated mRCC, and develop strategies to appropriately integrate these approaches in routine practice.
  • Describe ongoing research to assist in the identification of biomarkers, tumor characteristics or other clinical features that are indicative of response to immune checkpoint inhibitors in patients with RCC.
  • Recognize immune-related adverse events and other common side effects associated with approved and investigational immune checkpoint inhibitor combination approaches, and use this information to develop supportive management plans for patients with RCC undergoing treatment with these agents.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination in the adjuvant and neoadjuvant settings, and counsel appropriately selected patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Toni K Choueiri, MD
  Director, Lank Center for Genitourinary Oncology
  Department of Medical Oncology
  Dana-Farber Cancer Institute
  Co-Leader, Kidney Cancer Program
  Dana-Farber/Harvard Cancer Center
  The Jerome and Nancy Kohlberg Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee and Consulting Agreements: Alexion Pharmaceuticals, Analysis Group, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Daré Bioscience, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Peloton Therapeutics Inc, Pfizer Inc, Prometheus Laboratories Inc, Roche Laboratories Inc, Sanofi Genzyme; Contracted Research: Alexion Pharmaceuticals, Analysis Group, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Corvus Pharmaceuticals, Daré Bioscience, Eisai Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Foundation Medicine, Genentech, GlaxoSmithKline, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Peloton Therapeutics Inc, Pfizer Inc, Prometheus Laboratories Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, TRACON Pharmaceuticals Inc; Honoraria: Alexion Pharmaceuticals, Analysis Group, Apollo Endosurgery Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Daré Bioscience, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Foundation Medicine, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Peloton Therapeutics Inc, Pfizer Inc, Prometheus Laboratories Inc, Roche Laboratories Inc, Sanofi Genzyme.
  
  Thomas Powles, MBBS, MRCP, MD
  Professor of Genitourinary Oncology
  Barts Cancer Institute
  Director of Barts Cancer Centre
  Queen Mary University of London
  London, United Kingdom
  
  Consulting Agreements: Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Seattle Genetics.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Pfizer Inc and EMD Serono Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: July 2019
  Expiration date: July 2020